Business Wire | Aug 5, 2020 08:00AM EDT

Catabasis Pharmaceuticals to Present at Virtual 2020 Wedbush PacGrow Healthcare Conference

Aug. 05, 2020

BOSTON--(BUSINESS WIRE)--Aug. 05, 2020--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview at the virtual 2020 Wedbush PacGrow Healthcare Conference on Wednesday, August 12, 2020 at 8:00am ET.

A webcast of the presentation will be available on the investors section of the Company's website, www.catabasis.com, and will be archived for 30 days following the presentation.

About Catabasis

At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in Phase 3 development for the treatment of Duchenne muscular dystrophy. For more information on edasalonexent and our Phase 3 PolarisDMD trial, please visit www.catabasis.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200805005081/en/

CONTACT: Catabasis Investor and Media Contact Andrea Matthews Catabasis Pharmaceuticals, Inc. T: (617) 349-1971 amatthews@catabasis.com